Intrathecal drug delivery for chronic pain management-scope, limitations and future

Abstract

Intrathecal drug delivery system (IDDS) is a targeted therapy system for treating pain and muscle spasm. IDDS is recommended for the treatment of chronic pain which does not respond to optimal medical management. The aim of this review article is to give an up to date and concise account of the use of IDDS. It will explore the main indications, pre-implantation trials and different implantation techniques, the licensing of drugs for intrathecal use and the adverse effects and benefits of this therapy. IDDS is an invasive technique, which can result in severe morbidity and mortality. The up to date knowledge gained from this article along with the recommendations for improving safety in patients receiving IDDS, makes it a valuable resource for healthcare practitioners. Continued research, including outcome studies of this therapy continues to be necessary.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Cohen SP, Dragovich A. Intrathecal analgesia. Anesthesiol Clin. 2007;25(4):863–82.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Stearns L, Boortz-Marx R, Du Pen S, Friehs G, Gordon M, Halyard M, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3(6):399–408.

    CAS  PubMed  Google Scholar 

  3. 3.

    Deer T, Winkelmüller W, Erdine S, Bedder M, Burchiel K. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management. Neuromodulation. 1999;2(2):55–66.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Smith TJ, Coyne PJ. How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Support Oncol. 2003;1(1):73–6.

    PubMed  Google Scholar 

  5. 5.

    Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch SJ, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5(3):239–47.

    Article  PubMed  Google Scholar 

  6. 6.

    Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H. Intrathecal drug delivery. Pain Physician. 2008;11(2 Suppl):S89–104.

    PubMed  Google Scholar 

  7. 7.

    Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manag. 1996;11(2):71–80.

    Article  CAS  Google Scholar 

  8. 8.

    Koulousakis A, Kuchta J, Bayarassou A, Sturm V. Intrathecal opioids for intractable pain syndromes. Acta Neurochir Suppl. 2007;97(Pt 1):43–8.

    CAS  PubMed  Google Scholar 

  9. 9.

    Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–9.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Hassenbusch SJ, Portenoy RK, Cousins M, Buchser E, Deer TR, Du Pen SL, et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery—report of an expert panel. J Pain Symptom Manage. 2004;27(6):540–63.

    Article  PubMed  Google Scholar 

  11. 11.

    Knight KH, Brand FM, Mchaourab AS, Veneziano G. Implantable intrathecal pumps for chronic pain: highlights and updates. Croat Med J. 2007;48(1):22–34.

    PubMed Central  PubMed  Google Scholar 

  12. 12.

    Deer TR, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14(3):E283–312.

    PubMed  Google Scholar 

  13. 13.

    Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010(1):CD006605.

  14. 14.

    Clark JD. Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manag. 2002;23(2):131–7.

    Article  Google Scholar 

  15. 15.

    Patel VB, Manchikanti L, Singh V, Schultz DM, Hayek SM, Smith HS. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician. 2009;12(2):345–60.

    PubMed  Google Scholar 

  16. 16.

    Raphael JH, Duarte RV, Southall JL, Nightingale P, Kitas GD. Randomised, double-blind controlled trial by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain. BMJ Open. 2013;3(7). pii: e003061. doi:10.1136/bmjopen-2013-003061.

  17. 17.

    Duarte RV, Raphael JH, Sparkes E, Southall JL, LeMarchand K, Ashford RL. Long-term intrathecal drug administration for chronic nonmalignant pain. J Neurosurg Anesthesiol. 2012;24(1):63–70.

    Article  PubMed  Google Scholar 

  18. 18.

    Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med. 2011;12(10):1481–9.

    Article  PubMed  Google Scholar 

  19. 19.

    Deer TR, Prager J, Levy R, Burton A, Buchser E, Caraway D, et al. Polyanalgesic consensus conference—2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15(5):420–35; discussion 35.

  20. 20.

    Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic consensus conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15(5):436–64; discussion 64–66.

  21. 21.

    Plummer JL, Cmielewski PL, Gourlay GK, Owen H, Cousins MJ. Antinociceptive and motor effects of intrathecal morphine combined with intrathecal clonidine, noradrenaline, carbachol or midazolam in rats. Pain. 1992;49(1):145–52.

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Siddall PJ, Molloy AR, Walker S, Mather LE, Rutkowski SB, Cousins MJ. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg. 2000;91(6):1493–8.

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    Mercadante S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain. 1999;79(1):1–13.

    Article  CAS  PubMed  Google Scholar 

  24. 24.

    Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery. 1999;44(2):289–300; discussion-1.

  25. 25.

    Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85(6):2215–22.

    Article  CAS  PubMed  Google Scholar 

  26. 26.

    Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9(2):75–86.

    Article  PubMed  Google Scholar 

  27. 27.

    van Hilten BJ, van de Beek WJ, Hoff JI, Voormolen JH, Delhaas EM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med. 2000;343(9):625–30.

    Article  PubMed  Google Scholar 

  28. 28.

    Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag. 2006;31(5):393–406.

    Article  CAS  Google Scholar 

  29. 29.

    Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291(1):63–70.

    Article  CAS  PubMed  Google Scholar 

  30. 30.

    Hildebrand KR, Elsberry DD, Deer TR. Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system. Clin J Pain. 2001;17(3):239–44.

    Article  CAS  PubMed  Google Scholar 

  31. 31.

    Rudich Z, Peng P, Dunn E, McCartney C. Stability of clonidine in clonidine-hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients. J Pain Symptom Manag. 2004;28(6):599–602.

    Article  CAS  Google Scholar 

  32. 32.

    Taira T, Kawamura H, Tanikawa T, Iseki H, Kawabatake H, Takakura K. A new approach to control central deafferentation pain: spinal intrathecal baclofen. Stereotact Funct Neurosurg. 1995;65(1–4):101–5.

    Article  CAS  PubMed  Google Scholar 

  33. 33.

    Mekhail N, Mahboobi R, Farajzadeh Deroee A, Costandi S, Dalton J, Guirguis M, et al. Factors that might impact intrathecal drug delivery (IDD) dose escalation: a longitudinal study. Pain Pract. 2014;14(4):301–08.

  34. 34.

    Lim HS, Kim JM, Choi JG, Ko YK, Shin YS, Jeon BH, et al. Intrathecal ketamine and pregabalin at sub-effective doses synergistically reduces neuropathic pain without motor dysfunction in mice. Biol Pharm Bull. 2013;36(1):125–30.

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    Engle MP, Vinh BP, Harun N, Koyyalagunta D. Infectious complications related to intrathecal drug delivery system and spinal cord stimulator system implantations at a comprehensive cancer pain center. Pain Physician. 2013;16(3):251–7.

    PubMed  Google Scholar 

  36. 36.

    Follett KA, Boortz-Marx RL, Drake JM, DuPen S, Schneider SJ, Turner MS, et al. Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections. Anesthesiology. 2004;100(6):1582–94.

    Article  PubMed  Google Scholar 

  37. 37.

    Duarte RV, Raphael JH, Southall JL, Baker C, Hanu-Cernat D. Intrathecal inflammatory masses: is the yearly opioid dose increase an early indicator? Neuromodulation. 2010;13(2):109–13.

    Article  PubMed  Google Scholar 

  38. 38.

    Coffey RJ, Owens ML, Broste SK, Dubois MY, Ferrante FM, Schultz DM, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology. 2009;111(4):881–91.

    Article  PubMed  Google Scholar 

  39. 39.

    Gaiser RR, Berkowitz DH, Chou D. Epidural blood patch in a patient taking enoxaparin. J Clin Anesth. 2004;16(5):386–8.

    Article  PubMed  Google Scholar 

  40. 40.

    Duarte RV, Raphael JH, Haque MS, Southall JL, Ashford RL. A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. Pain Physician. 2012;15(5):363–9.

    PubMed  Google Scholar 

  41. 41.

    Duarte RV, Raphael JH, Southall JL, Labib MH, Whallett AJ, Ashford RL. Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy. BMJ Open. 2013;3:e002856. doi:10.1136/bmjopen-2013-002856.

  42. 42.

    Finch PM, Price LM, Pullan PT, Drummond PD. Effects of testosterone treatment on bone mineral density in hypogonadal men receiving intrathecal opioids. Pain Pract. 2014. doi:10.1111/papr.12190.

  43. 43.

    Prager J, Deer T, Levy R, Bruel B, Buchser E, Caraway D, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17(4):354–72.

    Article  PubMed  Google Scholar 

  44. 44.

    Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996;85(3):458–67.

    Article  PubMed  Google Scholar 

  45. 45.

    Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007;10(2):357–66.

    PubMed  Google Scholar 

  46. 46.

    Roberts LJ, Finch PM, Goucke CR, Price LM. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001;5(4):353–61.

    Article  CAS  PubMed  Google Scholar 

  47. 47.

    Cheng JK, Chen CC, Yang JR, Chiou LC. The antiallodynic action target of intrathecal gabapentin: Ca2+ channels, KATP channels or N-methyl-d-aspartic acid receptors? Anesth Analg. 2006;102(1):182–7.

    Article  CAS  PubMed  Google Scholar 

  48. 48.

    Belfrage M, Segerdahl M, Arnér S, Sollevi A. The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain. Anesth Analg. 1999;89(1):136–42.

    CAS  PubMed  Google Scholar 

  49. 49.

    Karlsten R, Gordh T. An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth Analg. 1995;80(4):844–7.

    CAS  PubMed  Google Scholar 

  50. 50.

    Rane K, Segerdahl M, Goiny M, Sollevi A. Intrathecal adenosine administration: a phase 1 clinical safety study in healthy volunteers, with additional evaluation of its influence on sensory thresholds and experimental pain. Anesthesiology. 1998;89(5):1108–15; discussion 9A.

  51. 51.

    Nielsen CK, Lewis RJ, Alewood D, Drinkwater R, Palant E, Patterson M, et al. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain. 2005;118(1–2):112–24.

    Article  CAS  PubMed  Google Scholar 

  52. 52.

    Szabo T, Olah Z, Iadarola MJ, Blumberg PM. Epidural resiniferatoxin induced prolonged regional analgesia to pain. Brain Res. 1999;840(1–2):92–8.

    Article  CAS  PubMed  Google Scholar 

  53. 53.

    Deer T, Krames ES, Hassenbusch S, Burton A, Caraway D, Dupen S, et al. Future directions for intrathecal pain management: a review and update from the interdisciplinary polyanalgesic consensus conference 2007. Neuromodulation. 2008;11(2):92–7.

    Article  PubMed  Google Scholar 

  54. 54.

    Kan J, Yang Z, Tang K, Cheng G. Pumping performance of a new piezoelectric pump for drug delivery. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004;21(2):297–301.

    PubMed  Google Scholar 

  55. 55.

    Kunnumpurath S, Srinivasagopalan R, Vadivelu N. Spinal cord stimulation: principles of past, present and future practice: a review. J Clin Monit Comput. 2009;23(5):333–9.

    Article  PubMed  Google Scholar 

  56. 56.

    Onofrio BM, Yaksh TL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J Neurosurg. 1990;72(2):200–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors of manuscript “Intrathecal Drug Delivery for Chronic Pain Management-Scope, Limitations and Future” declare that they have no conflict of interest. The Authors have no relevant financial relationships to declare.

Author information

Affiliations

Authors

Corresponding author

Correspondence to M. Czernicki.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Czernicki, M., Sinovich, G., Mihaylov, I. et al. Intrathecal drug delivery for chronic pain management-scope, limitations and future. J Clin Monit Comput 29, 241–249 (2015). https://doi.org/10.1007/s10877-014-9607-1

Download citation

Keywords

  • Chronic non-malignant pain
  • Cancer pain
  • Intrathecal drug delivery system